Literature DB >> 20919885

Altitude illness in Qinghai–Tibet railroad passengers.

Tian Yi Wu1, Shou Quan Ding, Sheng Lin Zhang, Jin Qing Duan, Bao Yu Li, Zhong Yan Zhan, Qin Li Wu, Suolung Baomu, Bao Zhu Liang, Shu Rang Han, Yu Ling Jie, Gang Li, Lin Sun, Bengt Kayser.   

Abstract

It takes ≈24 h to travel the ≈3000-km-long Qinghai–Tibet railroad of which 85% is situated above 4000 m with a pass at 5072 m. Each year about 2 million passengers are rapidly exposed to high altitude traveling on this train. The aim of this study was to quantify the occurrence of altitude illness on the train. Three subject groups were surveyed: 160 Han lowlanders, 62 Han immigrants living at 2200 to 2500 m, and 25 Tibetans living at 3700 to 4200 m. Passengers reached 4768 m from 2808 m in less than 1.5 h, after which 78% of the passengers reported symptoms, 24% reaching the Lake Louise criterion score for AMS. AMS incidence was 31% in nonacclimatized Han compared to 16% in Han altitude residents and 0% in Tibetans. Women and older subjects had a slightly greater risk for AMS. Most cases of AMS were mild and self-limiting, resolving within days upon arrival in Lhasa. Some cases of more severe AMS necessitated medical attention. To curb the health risk of rapid travel to altitude by train, prospective travelers should be better informed, medical train personnel should be well trained, and staged travel with 1 to 2 days at intermediate altitudes should be suggested to nonacclimatized subjects.

Entities:  

Mesh:

Year:  2010        PMID: 20919885     DOI: 10.1089/ham.2009.1047

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  9 in total

Review 1.  Obesity as a Conditioning Factor for High-Altitude Diseases.

Authors:  Rocío San Martin; Julio Brito; Patricia Siques; Fabiola León-Velarde
Journal:  Obes Facts       Date:  2017-08-16       Impact factor: 3.942

2.  Intermittent hypobaric hypoxia promotes atherosclerotic plaque instability in ApoE-deficient mice.

Authors:  Sihua Jiang; Feipeng Jin; De Li; Xingmei Zhang; Yun Yang; Dachun Yang; Kun Li; Yongjian Yang; Shuangtao Ma
Journal:  High Alt Med Biol       Date:  2013-06       Impact factor: 1.981

3.  Oxygen enrichment and its application to life support systems for workers in high-altitude areas.

Authors:  Yongling Li; Yingshu Liu
Journal:  Int J Occup Environ Health       Date:  2014 Jul-Sep

4.  Rhodiola crenulata extract for prevention of acute mountain sickness: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  Te-Fa Chiu; Lisa Li-Chuan Chen; Deng-Huang Su; Hsiang-Yun Lo; Chung-Hsien Chen; Shih-Hao Wang; Wei-Lung Chen
Journal:  BMC Complement Altern Med       Date:  2013-10-31       Impact factor: 3.659

5.  Acute mountain sickness, arterial oxygen saturation and heart rate among Tibetan students who reascend to Lhasa after 7 years at low altitude: a prospective cohort study.

Authors:  Espen Bjertness; Tianyi Wu; Hein Stigum; Per Nafstad
Journal:  BMJ Open       Date:  2017-07-10       Impact factor: 2.692

Review 6.  Sex-based differences in the prevalence of acute mountain sickness: a meta-analysis.

Authors:  Yun-Peng Hou; Jia-Lin Wu; Chao Tan; Yu Chen; Rui Guo; Yong-Jun Luo
Journal:  Mil Med Res       Date:  2019-12-09

7.  Effect of Carbohydrate-Electrolyte Solution Including Bicarbonate Ion Ad Libitum Ingestion on Urine Bicarbonate Retention during Mountain Trekking: A Randomized, Controlled Pilot Study.

Authors:  Masahiro Horiuchi; Tatsuya Hasegawa; Hiroshi Nose
Journal:  Int J Environ Res Public Health       Date:  2021-02-04       Impact factor: 3.390

8.  A specific objective supplemental factor in evaluating acute mountain sickness: ΔHR in combination with SaO2.

Authors:  Ming Li; Ji-Hang Zhang; Guo-Xi Zhao; Shi-Zhu Bian; Xu-Bin Gao; Xi Liu; Jie Yu; Jun-Qing Dong; Guo-Zhu Chen; Hong Wang; Lan Huang
Journal:  Mil Med Res       Date:  2015-10-26

9.  Differences Between the "Chinese AMS Score" and the Lake Louise Score in the Diagnosis of Acute Mountain Sickness.

Authors:  Jialin Wu; Haoran Gu; Yongjun Luo
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.